Valeant Pharmaceuticals International, Inc.
The pharmaceutical company can leverage asset sales to pay off its debt load
The pharmaceutical company has continued to meet or exceed expectations
The pharmaceutical company’s swap option indicates that its equity is not worth nothing, according to an Evercore ISI analyst
Valeant is likely to focus on core business segments and use proceeds from sale of non-core assets to de-lever itself
A Cantor Fitzgerald analyst remains optimistic over the pharmaceutical company's solid execution and future growth prospects